Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This is a Phase I, single-center, open label parallel-group, randomized study designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of single and repeated oral doses of Linaprazan Glurate for up to 14 days at 3 dose levels in healthy male and female subjects. The subjects will be followed up to 28 days post IMP dosing.
Epistemonikos ID: 2317f113cbdaaf1817a4b587565e294a76c708aa
First added on: Feb 19, 2024